Abstract P2-07-11

In this video, Prof François Duhoux meets up with Dr Christophe Van Berckelaer to discuss the results of a retrospective study looking at the value of baseline staging tests in early-stage breast cancer. This real-life study revealed a very low prevalence of metastases in early-stage breast cancer (T1/2N0). In addition, the study revealed a high rate of false positive staging results, which can lead to psychological distress in patients. As such, these findings support guidelines stating that routine baseline staging can generally be omitted in this setting. Interestingly, the percentage of patients with a positive staging was somewhat higher among patients with an elevated CA15.3 level, identifying a group of patients in whom these staging tests can still be considered..